Cargando…
Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colore...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205207/ https://www.ncbi.nlm.nih.gov/pubmed/37228916 http://dx.doi.org/10.1097/MS9.0000000000000694 |
_version_ | 1785045986075213824 |
---|---|
author | Rudiman, Reno Wijaya, Alma Sribudiani, Yunia Soedjana, Hardi Siswo Wiraswati, Hesti Lina Primastari, Etis Nugraha, Prapanca Lukman, Kiki |
author_facet | Rudiman, Reno Wijaya, Alma Sribudiani, Yunia Soedjana, Hardi Siswo Wiraswati, Hesti Lina Primastari, Etis Nugraha, Prapanca Lukman, Kiki |
author_sort | Rudiman, Reno |
collection | PubMed |
description | In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colorectal cancer patients diagnosed after metastases, some patients will develop metastases after undergoing surgical resection of the primary tumor. The survival of metastatic colorectal cancer patients has improved significantly in the last 20 years with the introduction of target-oriented drugs, anti–epidermal growth factor receptor (EGFR), and anti–human epidermal growth factor receptor-2 (HER2). This study aims to assess the relationship between Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and HER2 expression for targeted therapy implementation. PATIENTS AND METHODS: This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the digestive surgery division. There were 58 study subjects. Examination of KRAS mutations was carried out by PCR on fresh tumor tissue obtained from surgery or colonoscopy. Meanwhile, the HER2 examination used the immunohistochemistry method of paraffin blocks for anatomical pathology examination. RESULTS: Examination of KRAS mutations showed 28/58 (43.8%) patients with colorectal cancer, while HER2 overexpression was found in 6/58 (10.3%) patients with colorectal cancer. Univariate analysis of KRAS mutations and HER2 expression showed that four subjects with KRAS mutations had excess HER2 expression (P=0.341). CONCLUSION: There is no association between KRAS mutations and HER2 overexpression in colorectal cancer patients. |
format | Online Article Text |
id | pubmed-10205207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-102052072023-05-24 Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study Rudiman, Reno Wijaya, Alma Sribudiani, Yunia Soedjana, Hardi Siswo Wiraswati, Hesti Lina Primastari, Etis Nugraha, Prapanca Lukman, Kiki Ann Med Surg (Lond) Original Research In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colorectal cancer patients diagnosed after metastases, some patients will develop metastases after undergoing surgical resection of the primary tumor. The survival of metastatic colorectal cancer patients has improved significantly in the last 20 years with the introduction of target-oriented drugs, anti–epidermal growth factor receptor (EGFR), and anti–human epidermal growth factor receptor-2 (HER2). This study aims to assess the relationship between Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and HER2 expression for targeted therapy implementation. PATIENTS AND METHODS: This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the digestive surgery division. There were 58 study subjects. Examination of KRAS mutations was carried out by PCR on fresh tumor tissue obtained from surgery or colonoscopy. Meanwhile, the HER2 examination used the immunohistochemistry method of paraffin blocks for anatomical pathology examination. RESULTS: Examination of KRAS mutations showed 28/58 (43.8%) patients with colorectal cancer, while HER2 overexpression was found in 6/58 (10.3%) patients with colorectal cancer. Univariate analysis of KRAS mutations and HER2 expression showed that four subjects with KRAS mutations had excess HER2 expression (P=0.341). CONCLUSION: There is no association between KRAS mutations and HER2 overexpression in colorectal cancer patients. Lippincott Williams & Wilkins 2023-04-17 /pmc/articles/PMC10205207/ /pubmed/37228916 http://dx.doi.org/10.1097/MS9.0000000000000694 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Original Research Rudiman, Reno Wijaya, Alma Sribudiani, Yunia Soedjana, Hardi Siswo Wiraswati, Hesti Lina Primastari, Etis Nugraha, Prapanca Lukman, Kiki Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study |
title | Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study |
title_full | Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study |
title_fullStr | Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study |
title_full_unstemmed | Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study |
title_short | Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study |
title_sort | identification of kras mutation and her2 expression in indonesian colorectal cancer population: a cross-sectional study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205207/ https://www.ncbi.nlm.nih.gov/pubmed/37228916 http://dx.doi.org/10.1097/MS9.0000000000000694 |
work_keys_str_mv | AT rudimanreno identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy AT wijayaalma identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy AT sribudianiyunia identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy AT soedjanahardisiswo identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy AT wiraswatihestilina identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy AT primastarietis identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy AT nugrahaprapanca identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy AT lukmankiki identificationofkrasmutationandher2expressioninindonesiancolorectalcancerpopulationacrosssectionalstudy |